Physician profile
David P Randall
NPI 1568521441
$8,812.67
in general payments reported to CMS, 2019-2025
13 companies · $459 in 2025
The $459 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $4,900 · 2021: $16.69 · 2022: $160 · 2023: $2,721 · 2024: $335 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,475 · Food and Beverage: $988 · Education: $52.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,475.00 |
| Food and Beverage | $988.24 |
| Education | $52.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $4,900.00 | 2020 | |
| Argenx US, INC. | $2,729.65 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $557.54 | 2021-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $213.89 | 2022-2025 | Hyqvia, Gammagard |
| Teva Pharmaceuticals USA, INC. | $120.12 | 2019 | |
| Abbvie INC. | $115.50 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $61.84 | 2019 | |
| Livanova USA, INC. | $21.35 | 2022 | |
| Abbott Laboratories | $21.13 | 2022 | |
| Lundbeck LLC | $20.98 | 2019 | |
| Tanabe Pharma America, INC. | $19.79 | 2024 | |
| Greenwich Biosciences, INC. | $17.71 | 2019 | |
| Ucb, INC. | $13.17 | 2024 | Rystiggo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Randall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.